51
|
Mocan T, Matea C, Tabaran F, Iancu C, Orasan R, Mocan L. In Vitro Administration of Gold Nanoparticles Functionalized with MUC-1 Protein Fragment Generates Anticancer Vaccine Response via Macrophage Activation and Polarization Mechanism. J Cancer 2015; 6:583-92. [PMID: 26000051 PMCID: PMC4439945 DOI: 10.7150/jca.11567] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2015] [Accepted: 04/13/2015] [Indexed: 12/17/2022] Open
Abstract
Therapeutic cancer vaccines (or active immunotherapy) aim to guide the patient's personal immune system to eradicate cancer cells. An exciting approach to cancer vaccines has been offered by nanoscale drug delivery systems containing tumor associated antigens (TAAs). Their capacity to stimulate the immune system has been suggested during late years. However, the role of the macrophages as key-elements in antigen-presentation process following TAAs-containing nanosystems is not completely understood. We aimed to evaluate the effect of gold nanoparticles functionalized with mucin-1 peptide (MUC-1) on murine peritoneal macrophages. Gold nanoparticles, obtained using a modified Turkevich method, were functionalized with MUC-1 protein using Clealand's reagent. The obtained GNP-MUC-1 solution was used to treat at various concentrations monolayers of peritoneum-derived macrophages that were further analyzed using confocal and hyperspectral microscopy, ELISA assays and spectroscopic techniques. The GNP-MUC-1 nano-construct had proven to function as a powerful macrophage activator with consequent release of cytokines such as: TNF-ɑ, IL-6, IL-10 and IL-12 on peritoneal macrophages we have isolated from mice. Our results demonstrate optimization of antigen-presenting process and predominant M1 polarization following exposure GNP-MUC-1. To our best knowledge this is the first study to evaluate the anticancer effects of a newly designed nano-biocompound on the complex antigen- processing apparatus of peritoneal macrophages.
Collapse
Affiliation(s)
- Teodora Mocan
- 2. Department of Nanomedicine, Institute of Gastroenterology and Hepatology, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania
- 3. Department of Physiology, “Iuliu Hatieganu” University of Medicine and Pharmacy, no. 1 Clinicilor Street., 400006 Cluj-Napoca, Romania
| | - Cristian Matea
- 1. 3rd Surgery Clinic, “Iuliu Hatieganu” University of Medicine and Pharmacy, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania
- 2. Department of Nanomedicine, Institute of Gastroenterology and Hepatology, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania
| | - Flaviu Tabaran
- 2. Department of Nanomedicine, Institute of Gastroenterology and Hepatology, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania
- 4. Department of Pathology, Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania; Calea Mănăștur 3-5, Cluj-Napoca 400372
| | - Cornel Iancu
- 1. 3rd Surgery Clinic, “Iuliu Hatieganu” University of Medicine and Pharmacy, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania
- 2. Department of Nanomedicine, Institute of Gastroenterology and Hepatology, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania
| | - Remus Orasan
- 3. Department of Physiology, “Iuliu Hatieganu” University of Medicine and Pharmacy, no. 1 Clinicilor Street., 400006 Cluj-Napoca, Romania
| | - Lucian Mocan
- 1. 3rd Surgery Clinic, “Iuliu Hatieganu” University of Medicine and Pharmacy, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania
- 2. Department of Nanomedicine, Institute of Gastroenterology and Hepatology, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania
| |
Collapse
|
52
|
Amin M, Lockhart AC. The potential role of immunotherapy to treat colorectal cancer. Expert Opin Investig Drugs 2014; 24:329-44. [PMID: 25519074 DOI: 10.1517/13543784.2015.985376] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
INTRODUCTION Colorectal cancer (CRC) is the fourth most common cancer and the second leading cause of cancer-related death worldwide. Surgery, chemotherapy, radiation therapy and anti-angiogenic therapies form the backbone of treatment for CRC in various stages. Immunotherapy is frequently used either alone or in combination with chemotherapy for the treatment of various cancers such as melanoma, prostate cancer and renal cell cancer. Current CRC research is moving forward to discover ways to incorporate immunotherapies into the treatment of CRC. AREAS COVERED The aim of this review is to summarize the potential role of immunotherapy in CRC. Herein, the authors provide a brief overview of immune modulatory cells, immune surveillance and escape in CRC. They also review vaccine trials in addition to cytokines and monoclonal antibodies. This coverage includes ongoing trials and checkpoint inhibitors such as cytotoxic T lymphocyte antigen-1, programmed cell death-1, and PDL1. EXPERT OPINION Checkpoint inhibitors in combination with either chemotherapy or chemo-antiangiogenic-therapy may represent a future therapeutic approach for CRC incorporating immune system targeting. Given the success of immune-based therapy in other tumor types, the authors anticipate that a similar breakthrough in CRC will be forthcoming.
Collapse
Affiliation(s)
- Manik Amin
- Washington University, Siteman Cancer Center , 660 S. Euclid Ave, Box 8056, St. Louis, MO 63110 , USA
| | | |
Collapse
|
53
|
Shahbazi MA, Fernández TD, Mäkilä EM, Le Guével X, Mayorga C, Kaasalainen MH, Salonen JJ, Hirvonen JT, Santos HA. Surface chemistry dependent immunostimulative potential of porous silicon nanoplatforms. Biomaterials 2014; 35:9224-35. [DOI: 10.1016/j.biomaterials.2014.07.050] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Accepted: 07/23/2014] [Indexed: 02/02/2023]
|
54
|
Rosenthal JA, Chen L, Baker JL, Putnam D, DeLisa MP. Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale. Curr Opin Biotechnol 2013; 28:51-8. [PMID: 24832075 DOI: 10.1016/j.copbio.2013.11.005] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2013] [Revised: 11/07/2013] [Accepted: 11/13/2013] [Indexed: 12/24/2022]
Abstract
Vaccine adjuvants are an essential component of vaccine design, helping to generate immunity to pathogen antigens in the absence of infection. Recent advances in nanoscale engineering have created a new class of particulate bionanotechnology that uses biomimicry to better integrate adjuvant and antigen. These pathogen-like particles, or PLPs, can come from a variety of sources, ranging from fully synthetic platforms to biologically derived, self-assembling systems. By employing molecularly engineered targeting and stimulation of key immune cells, recent studies utilizing PLPs as vaccine delivery platforms have shown great promise against high-impact, unsolved vaccine targets ranging from bacterial and viral pathogens to cancer and addiction.
Collapse
Affiliation(s)
- Joseph A Rosenthal
- Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA
| | - Linxiao Chen
- School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853, USA
| | - Jenny L Baker
- School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853, USA
| | - David Putnam
- Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA; School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853, USA.
| | - Matthew P DeLisa
- Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA; School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853, USA.
| |
Collapse
|
55
|
Park YM, Lee SJ, Kim YS, Lee MH, Cha GS, Jung ID, Kang TH, Han HD. Nanoparticle-based vaccine delivery for cancer immunotherapy. Immune Netw 2013; 13:177-83. [PMID: 24198742 PMCID: PMC3817298 DOI: 10.4110/in.2013.13.5.177] [Citation(s) in RCA: 85] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Revised: 09/09/2013] [Accepted: 09/13/2013] [Indexed: 12/16/2022] Open
Abstract
Development of nano-sized carriers including nanoparticles, nanoemulsions or liposomes holds great potential for advanced delivery systems for cancer immunotherapy, as such nanostructures can be used to more effectively manipulate or deliver immunologically active components to specific target sites. Successful development of nanotechnology based platform in the field of immunotherapy will allow the application of vaccines, adjuvants and immunomodulatory drugs that improve clinical outcomes for immunological diseases. Here, we review current nanoparticle-based platforms in the efficacious delivery of vaccines in cancer immunotherapy.
Collapse
Affiliation(s)
- Yeong-Min Park
- Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, Korea
| | - Seung Jun Lee
- Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, Korea
| | - Young Seob Kim
- Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, Korea
| | - Moon Hee Lee
- Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, Korea
| | - Gil Sun Cha
- Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, Korea
| | - In Duk Jung
- Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, Korea
| | - Tae Heung Kang
- Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, Korea
| | - Hee Dong Han
- Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, Korea
| |
Collapse
|